Regeneron Pharmaceuticals
Tracked across 9 events · 65 articles · First seen Jan 08, 2025 · Last active Jun 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received regulatory approvals for new indications, which is expected to positively impact its revenue and market position.
Feb 24, 2026 · 8 articles
Business
Impact: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
Business
Impact: Regeneron Pharmaceuticals, Inc. entered a strategic collaboration with Telix Pharmaceuticals Limited to jointly develop and commercialize next-generation radiopharmaceutical therapies, expanding its oncology portfolio and entering the targeted radiopharmaceuticals space.
Apr 12, 2026 · 6 articles
Tech
Impact: Regeneron Pharmaceuticals partly funds and supports Atara Biotherapeutics in developing therapies for diseases like inflammatory bowel disease, leveraging the Nobel-winning research.
Oct 06, 2025 · 6 articles
Regulatory
Impact: Regeneron Pharmaceuticals is expected to announce a deal with the Donald Trump administration after the holidays.
Dec 19, 2025 · 7 articles
Tech
Impact: Regeneron Pharmaceuticals is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Regeneron Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard